ArticleBlood2011
RhoJ is an endothelial cell-restricted Rho GTPase that mediates vascular morphogenesis and is regulated by the transcription factor ERG.
Article in Blood, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it, 83 citations in OpenAlex.
- The Role of RhoJ in Endothelial Cell Biology and Tumor Pathology.BioMed research international · 2016Pooled it
- Genome-Wide Association Analysis of Single-Breath DlAmerican journal of respiratory cell and molecular biology · 2019Trial
- Endothelial cell-specific DNA methylation alterations in breast cancer.Communications biology · 2026Article
- Metabolic reprogramming and interventions in angiogenesis.Journal of advanced research · 2025Review
- RhoJ: an emerging biomarker and target in cancer research and treatment.Cancer gene therapy · 2024Review
- Aging aggravates aortic aneurysm and dissection via miR-1204-MYLK signaling axis in mice.Nature communications · 2024Article
- Stiffness-induced modulation of ERG transcription factor in chronic liver disease.Npj gut and liver · 2024Article
- Elucidating the Associated Biological Function and Clinical Significance ofInternational journal of molecular sciences · 2023Article
- ETV2/ER71, the key factor leading the paths to vascular regeneration and angiogenic reprogramming.Stem cell research & therapy · 2023Review
- RHOJ Induces Epithelial-to-Mesenchymal Transition by IL-6/STAT3 to Promote Invasion and Metastasis in Gastric Cancer.International journal of biological sciences · 2023Article
- DOCK4 Regulation of Rho GTPases Mediates Pulmonary Vascular Barrier Function.Arteriosclerosis, thrombosis, and vascular biology · 2022Article
- Role of von Willebrand factor in the angiogenesis of lung adenocarcinoma.Oncology letters · 2022Review
- OVOL2 impairs RHO GTPase signaling to restrain mitosis and aggressiveness of Anaplastic Thyroid Cancer.Journal of experimental & clinical cancer research : CR · 2022Article
- Emerging roles of inflammation-mediated endothelial-mesenchymal transition in health and disease.Inflammation and regeneration · 2022Review
- Molecular basis for pericyte-induced capillary tube network assembly and maturation.Frontiers in cell and developmental biology · 2022Review
- Targeting Cancer by Using Nanoparticles to Modulate RHO GTPase Signaling.Advances in experimental medicine and biology · 2022Article
- RhoJ facilitates angiogenesis in glioblastoma via JNK/VEGFR2 mediated activation of PAK and ERK signaling pathways.International journal of biological sciences · 2022Article
- Identification of Endothelial Proteins in Plasma Associated With Cardiovascular Risk Factors.Arteriosclerosis, thrombosis, and vascular biology · 2021Article
- A functional antagonism between RhoJ and Cdc42 regulates fibronectin remodelling during angiogenesis.Small GTPases · 2021Article
- Dihydroartemisinin inhibits the expression of von Willebrand factor by downregulation of transcription factor ERG in endothelial cells.Fundamental & clinical pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 2 countries.
Funding
Abstract
ERG is a member of the ETS transcription factor family that is highly enriched in endothelial cells (ECs). To further define the role of ERG in regulating EC function, we evaluated the effect of ERG knock-down on EC lumen formation in 3D collagen matrices. Blockade of ERG using siRNA completely interferes with EC lumen formation. Quantitative PCR (QPCR) was used to identify potential downstream gene targets of ERG. In particular, we identified RhoJ as the Rho GTPase family member that is closely related to Cdc42 as a target of ERG. Knockdown of ERG expression in ECs led to a 75% reduction in the expression of RhoJ. Chromatin immunoprecipitation and transactivation studies demonstrated that ERG could bind to functional sites in the proximal promoter of the RhoJ gene. Knock-down of RhoJ similarly resulted in a marked reduction in the ability of ECs to form lumens. Suppression of either ERG or RhoJ during EC lumen formation was associated with a marked increase in RhoA activation and a decrease in Rac1 and Cdc42 activation and their downstream effectors. Finally, in contrast to other Rho GTPases, RhoJ exhibits a highly EC-restricted expression pattern in several different tissues, including the brain, heart, lung, and liver.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.